Aetna modified CPB 0464 for maternal biomarker screening, effective September 26, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated its maternal biomarker screening coverage policy under CPB 0464 Aetna system. This policy governs reimbursement for cell-free DNA fetal genotyping, NIPT for fetal aneuploidy, and multiple serum marker testing. The update affects 27 CPT codes, including 81420, 81507, 0488U, and 0494U — and tightens the criteria that determine whether a claim pays or denies.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Maternal Biomarker Screening for Fetal Conditions |
| Policy Code | CPB 0464 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | OB/GYN, Maternal-Fetal Medicine, Laboratory/Pathology, Women's Health |
| Key Action | Audit charge capture for NIPT and serum marker codes before submitting claims dated on or after September 26, 2025 |
Aetna Maternal Biomarker Screening Coverage Criteria and Medical Necessity Requirements 2025
The Aetna maternal biomarker screening coverage policy under CPB 0464 covers four main clinical scenarios. Each has hard criteria. If documentation doesn't match those criteria exactly, you're looking at a claim denial.
Cell-Free DNA for Fetal RhD Genotyping
Aetna covers cell-free DNA fetal genotyping for RhD status and other red cell antigens — think Natera's Fetal RhD (CPT 0494U) and the Unity Fetal Antigen NIPT (CPT 0488U) — when all three of the following are true:
| # | Covered Indication |
|---|---|
| 1 | The pregnancy may be at risk for alloimmunization due to maternal RhD status or the presence of red cell antigen antibodies |
| 2 | Paternal antigen typing is unavailable or heterozygous |
| 3 | Amniocentesis has been declined or is contraindicated |
All three criteria must be met. One or two isn't enough. Document each condition separately in the clinical notes, because a prior authorization request that only addresses alloimmunization risk without addressing paternal typing status will likely stall or deny.
One hard exclusion: tests limited to a single exon of the RHD gene are not covered. CPT 0536U — which analyzes only exon 4 of the RHD gene — falls into the non-covered group. This is a real trap if your lab or ordering provider defaults to the exon-specific assay.
Multiple Serum Marker Testing for Down Syndrome Risk
Medical necessity for the quad screen (dimeric inhibin A, hCG, MSAFP, and unconjugated estriol — billed under codes like 81510, 81511, 81512, 86336, 82105, 82677, 84702, and 84704) requires that the patient has been counseled and wants information about Down syndrome risk.
For women 35 and older, the policy follows USPSTF and ACOG guidance. CVS or amniocentesis is the recommended path for this age group. Aetna covers multiple serum marker testing for women in this group only if they decline the invasive procedures. Document that refusal. Without it, you don't have medical necessity under this policy.
NIPT for Fetal Aneuploidy
Aetna covers NIPT using cell-free fetal nucleic acid measurement — including CPT 81420, 81507, and 0327U — for fetal aneuploidy screening (trisomy 13, 18, 21, and sex chromosome aneuploidy) in all pregnant women. The policy lists approved tests by name:
| # | Covered Indication |
|---|---|
| 1 | ClariTest Core (chr 21, 18, 13, X, Y) |
| 2 | MaterniT21 PLUS Core (chr 21, 18, 13) — with or without gender |
| 3 | Panorama Prenatal Test (chr 21, 18, 13, X, Y only) |
| 4 | QNatal Advanced (21, 18, 13, X and Y) |
| 5 | Unity Aneuploidy Screen (chr 21, 18, 13, X, Y) — without 22q11.2 microdeletion or single-gene NIPT |
| 6 | Verifi Prenatal Test |
This list is not exhaustive, but it sets a clear benchmark. If you're billing for a test not on this list, verify coverage before assuming it qualifies. The named tests map primarily to CPT 81420, 81507, and 0327U depending on the specific platform.
NIPT After a Negative Serum Screen
Here's the one that will generate denials if you're not watching for it. Aetna considers NIPT not medically necessary when a patient already had a negative multiple serum marker screening test — with or without fetal nuchal translucency ultrasound — in the same pregnancy.
This is a sequencing rule. NIPT after a negative quad screen is not covered. Make sure your ordering workflow flags this scenario. A clean NIPT claim can become a denial the moment Aetna's system matches it to a prior negative serum screen for the same member in the same pregnancy.
Aetna Maternal Biomarker Screening Exclusions and Non-Covered Indications
Several codes under CPB 0464 are not covered. Aetna places them in a separate group labeled "Evaluation of DSCR4 gene methylation in plasma, measurement" — and the codes in that group include some that billing teams may be submitting under assumptions that don't hold.
CPT 81422 covers fetal chromosomal microdeletion genomic sequence analysis (e.g., DiGeorge syndrome). It's in the non-covered group. If your practice offers expanded NIPT panels that include 22q11.2 microdeletion detection, that add-on does not qualify under this policy.
CPT 0489U — single-gene NIPT — is also non-covered. This matters if you're billing for single-gene carrier screening layered onto a standard NIPT order.
CPT 0060U for twin zygosity testing is in the same non-covered group. CPT 0341U for fetal aneuploidy DNA sequencing from products of conception is similarly excluded.
CPT 83516 and 83520 for immunoassays, CPT 83632 for human placental lactogen, and CPT 84163 for PAPP-A are all grouped as non-covered under this policy. If your orders routinely include PAPP-A or HPL as standalone analytes, those claims will not pay under CPB 0464.
The pattern here is consistent. Aetna is covering standard aneuploidy screening and RhD genotyping. Expanded panels, single-gene NIPT, microdeletion testing, and ancillary analytes are out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cell-free DNA for fetal RhD genotyping | Covered (criteria required) | 0494U, 0488U | All three criteria must be met; single-exon tests excluded |
| Quad screen / multiple serum marker testing | Covered (criteria required) | 81510, 81511, 81512, 86336, 82105, 82677, 84702, 84703, 84704, 82106 | Women 35+ must decline CVS/amniocentesis; document counseling |
| NIPT for trisomy 13, 18, 21, sex chromosome aneuploidy | Covered (all pregnant women) | 81420, 81507, 0327U, 81403 | Named tests only; not covered if negative serum screen already on file |
| NIPT after negative serum screen (same pregnancy) | Not Medically Necessary | 81420, 81507, 0327U | Applies regardless of nuchal translucency result |
| 22q11.2 microdeletion NIPT | Not Covered | 81422 | Excluded even when bundled with covered aneuploidy screen |
| Single-gene NIPT | Not Covered | 0489U | Not covered as standalone or add-on |
| Twin zygosity testing | Not Covered | 0060U | Excluded under CPB 0464 |
| Fetal aneuploidy DNA from products of conception | Not Covered | 0341U | POC specimens excluded |
| PAPP-A standalone | Not Covered | 84163 | Covered in first-trimester panels only when criteria met |
| Human placental lactogen (HPL) | Not Covered | 83632 | Not covered under this policy |
| Immunoassay analytes (NOS) | Not Covered | 83516, 83520 | Anti-Müllerian hormone explicitly excluded under 83520 |
| RHD exon 4 PCR (single-exon test) | Not Covered | 0536U | Explicitly excluded in policy text |
Aetna Maternal Biomarker Screening Billing Guidelines and Action Items 2025
Here's what your billing team needs to do before submitting claims under CPB 0464.
| # | Action Item |
|---|---|
| 1 | Audit your NIPT charge capture now. For claims dated on or after September 26, 2025, confirm the test billed maps to a named covered platform. MaterniT21, Panorama, QNatal, Verifi, ClariTest, and Unity Aneuploidy are specifically listed. A generic NIPT order that doesn't specify a platform may not survive a medical necessity review. |
| 2 | Build a pre-claim check for the negative serum screen exclusion. Query your EHR or RCM system for members who had a quad screen or serum marker panel in the current pregnancy before the NIPT order was placed. If the prior screen was negative, NIPT maternal biomarker screening billing will not result in reimbursement. Flag these cases before claims go out. |
| 3 | Remove CPT 0536U from RhD genotyping orders. This code covers single-exon RHD analysis and is explicitly excluded. If your lab has been defaulting to exon 4 PCR, replace that order with CPT 0494U or 0488U when the full criteria for alloimmunization risk are met. |
| 4 | Document all three RhD coverage criteria in the prior authorization request. Aetna requires all three — alloimmunization risk, unavailable or heterozygous paternal typing, and declined/contraindicated amniocentesis. A prior auth that notes only maternal RhD status will likely be insufficient. Your ordering provider needs to address all three criteria in the clinical documentation. |
| 5 | Stop billing 81422, 0489U, and 84163 as covered under CPB 0464. These are explicitly non-covered. If 22q11.2 microdeletion or single-gene NIPT tests are part of your expanded panel offering, those claims need a different billing strategy. Talk to your compliance officer if you're uncertain whether a separate benefit or out-of-network arrangement applies before the September 26, 2025 effective date passes. |
| 6 | Update your quad screen documentation workflow for patients 35 and older. For this age group, medical necessity depends on documented refusal of CVS or amniocentesis. A missing refusal note is the fastest path to a denied serum marker claim. Add a required documentation field to your OB intake process if you haven't already. |
| 7 | Verify PAPP-A billing context. CPT 84163 is not covered as a standalone under this policy. PAPP-A as part of a first-trimester combined screen may flow through different coding depending on the panel. If your lab bills PAPP-A separately, check whether that standalone line is driving denials. |
If your practice has a high volume of expanded NIPT panels or specialized RhD testing, loop in your compliance officer before the effective date. The line between covered and non-covered under CPB 0464 is specific, and the financial exposure from systematic miscoding adds up fast.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Maternal Biomarker Screening Under CPB 0464
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 0327U | CPT | Fetal aneuploidy (trisomy 13, 18, and 21), DNA sequence analysis of selected regions using maternal cell-free DNA |
| 0488U | CPT | Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for red cell antigen detection |
| 0494U | CPT | Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA |
| 81403 | CPT | Molecular pathology procedure, Level 4 (single exon DNA sequence analysis) |
| 81420 | CPT | Fetal chromosomal aneuploidy genomic sequence analysis panel, circulating cell-free fetal DNA |
| 81507 | CPT | Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma |
| 81508 | CPT | Fetal congenital abnormalities, biochemical assays, two or three proteins (PAPP-A, hCG, or DIA) |
| 81509 | CPT | Fetal congenital abnormalities, biochemical assays, two or three proteins (PAPP-A, hCG, or DIA) — alternate trimester |
| 81510 | CPT | Fetal congenital abnormalities, biochemical assays — AFP, uE3, hCG, DIA |
| 81511 | CPT | Fetal congenital abnormalities, biochemical assays — AFP, uE3, hCG, DIA (four analytes) |
| 81512 | CPT | Fetal congenital abnormalities, biochemical assays — AFP, uE3, hCG, DIA (five analytes) |
| 82105 | CPT | Alpha-fetoprotein (AFP); serum |
| 82106 | CPT | Alpha-fetoprotein (AFP); amniotic fluid |
| 82677 | CPT | Estriol |
| 84702 | CPT | Gonadotropin, chorionic (hCG); quantitative |
| 84703 | CPT | Gonadotropin, chorionic (hCG); qualitative |
| 84704 | CPT | Gonadotropin, chorionic (hCG); free beta chain |
| 86336 | CPT | Inhibin A |
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0060U | CPT | Twin zygosity, genomic targeted sequence analysis of chromosome 2, circulating cell-free fetal DNA | Non-covered under CPB 0464 |
| 0341U | CPT | Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception | Non-covered under CPB 0464 |
| 0489U | CPT | Obstetrics (single-gene NIPT), cell-free DNA sequence analysis of one or more targeted variants | Single-gene NIPT excluded |
| 0536U | CPT | Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene only | Single-exon test explicitly excluded |
| 81422 | CPT | Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat) | Microdeletion NIPT excluded |
| 83516 | CPT | Immunoassay for analyte other than infectious agent; qualitative | Non-covered under CPB 0464 |
| 83520 | CPT | Immunoassay, analyte, quantitative; not otherwise specified (anti-Müllerian hormone explicitly excluded) | Non-covered under CPB 0464 |
| 83632 | CPT | Lactogen, human placental (HPL) / human chorionic somatomammotropin | Non-covered under CPB 0464 |
| 84163 | CPT | Pregnancy-associated plasma protein-A (PAPP-A) | Non-covered as standalone under CPB 0464 |
Key ICD-10-CM Diagnosis Codes
| Code Range | Description |
|---|---|
| O09.00–O99.893 / O9A.111–O9A.53 | Supervision of high-risk pregnancy; edema, proteinuria, and hypertensive disorders in pregnancy; childbirth-related conditions |
| Z03.71–Z03.79 / Z33.1 | Encounter for suspected maternal and fetal conditions ruled out; pregnant state, incidental |
| Z33.3 / Z34.00–Z36.9 | Encounter for supervision of normal pregnancy; encounter for antenatal screening |
Get the Full Picture for CPT 81420
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.